

EssilorLuxottica signs an agreement to acquire Espansione Group for accelerating its growth in the med-tech space

EssilorLuxottica strengthens its portfolio of advanced high-quality vision care instruments and certified medical technologies, with innovative solutions for dry-eye and other diseases

Paris, France (16 December 2024) – EssilorLuxottica announces that it has entered into an agreement for the acquisition of Espansione Group, an Italy-based company specialized in the design and manufacturing of non-invasive medical devices, protected by international patents, for the diagnosis and treatment of dry-eye, ocular surface and retinal diseases.

Espansione Group is a med-tech pioneer delivering the highest medical standards in over 40 countries. With the photobiomodulation (PBM) technology – the Light Modulation Low-level Light Therapy (LLLT) – for use in medical fields such as ophthalmology and dermatology, along with the Intense Pulsed Light (IPL) technology.

The agreement represents for EssilorLuxottica another step forward in the med-tech space and it is consistent with the Group’s strategy in elevating industry standards and improving the quality of patient care solutions.

Francesco Milleri, Chairman and Chief Executive Officer at EssilorLuxottica, commented: *“We are pleased to welcome the pioneering Espansione into our Group. This investment, proudly made in one of our home countries, will expand our portfolio of medical devices and solidify our role in the optical industry. EssilorLuxottica’s med-tech journey, aimed at elevating vision health standards, will continue to be an open and collaborative one, where our products and services are accessible to all industry players.”*

The transaction is subject to local regulatory review and other customary closing conditions.

Contacts

Giorgio Iannella

Head of Investor Relations
E ir@essilorluxottica.com

Marco Catalani

Head of Corporate Communications
E media@essilorluxottica.com

About EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. With over 200,000 employees across 150 countries, 650 operations facilities and 18,000 stores, in 2023 the Company generated consolidated revenue of Euro 25.4 billion. Its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. EssilorLuxottica is home to the most advanced lens technologies including Varilux, Stellest and Transitions, the most iconic eyewear brands including Ray-Ban and Oakley, the most desired luxury licensed brands and world-class retailers including LensCrafters and Sunglass Hut. The Company’s OneSight EssilorLuxottica Foundation has given access to sustainable vision care to more than 760 million people in underserved communities. The EssilorLuxottica share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESLX.PA; Bloomberg: EL:FP. www.essilorluxottica.com